KRAS and NRAS are members of the RAS family of genes, which encode proteins that regulate cell growth and division through ...

Silexion Therapeutics Corp has completed a significant preclinical study evaluating its RNA interference therapeutic candidate, SIL204, for various KRAS-driven cancers, including colorectal and ...

Discovered and developed by Lilly researchers, Verzenio was first approved in 2017 and is currently authorized for use in more than 90 counties around the world. For full details on indicated uses of ...

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...

Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

The investigational assay prospectively assesses KRAS status in patients with recurrent LGSOC to group patients into KRAS-mutation or KRAS-wild type cohorts for analysis in the primary and ...

On May 8, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib for ...

Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen's Lumakras & Bristol Myers' Krazati ...

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...